Obesity medications after bariatric surgery: youth outcomes

What happened: obesity medications after bariatric surgery in youths

Early reinitiation of obesity medications after bariatric surgery was associated with greater one-year weight loss in adolescents and young people who had sleeve gastrectomy (SG), according to a research letter published online July 22 in JAMA Surgery.

In the analysis, 53 of 99 youths restarted obesity medications after SG, with a median time to reinitiation of 1.0 month, and this group showed larger 12-month reductions in BMI percentage and excess BMI loss than those who had SG alone.

• Source: JAMA Surgery research letter (published online July 22, 2026).
• Population studied: youths ages 7–20 who underwent sleeve gastrectomy from November 2023 to February 2026.
• Medication context: obesity medications included glucagon-like peptide-1 (GLP-1) receptor agonists.

What the evidence shows about obesity medications after bariatric surgery

This was an analysis of 99 youths ages 7–20 who underwent sleeve gastrectomy, comparing 12-month safety, weight trajectory, and eating behavior outcomes between those who restarted obesity medications early and those who did not.

Through six months, both groups had similar early postoperative weight loss, but at 12 months the early reinitiation group had greater mean BMI percentage reduction (−29.3% vs −25.5%) and greater excess BMI loss percentage (−53.6% vs −45.7%) than the SG-only group.

• Eating behaviors: improvements at 12 months were significantly greater with early reinitiation (example: median hunger Adult Eating Behavior Questionnaire score change, −3.5 vs 0.2).
• Safety signals: no difference between groups in postoperative complications, including biliary events requiring cholecystectomy, readmissions, emergency department visits, and reoperations.
• Medication patterns: most youths resumed the same preoperative medication class; postoperative regimens were generally consolidated, with fewer youths needing multiagent therapy after surgery.

Why this matters for metabolic health planning

The findings add support to a “multimodal” obesity treatment approach in which obesity medications after bariatric surgery may be part of longer-term management, rather than viewing surgery and medication as competing options.

In a statement included with the report, study author Alaina P. Vidmar, MD (Children’s Hospital Los Angeles) said, “Bariatric surgery is the most durable and effective treatment for severe obesity, but for youth with severe disease, we need a multimodal approach, which means combining medication and surgery over the lifespan.”

Practical context: how this might show up in real care

In this cohort, “early” reinitiation meant restarting obesity medications soon after SG, with a median time of 1.0 month, and the main weight differences versus SG alone emerged by 12 months rather than in the first six months.

If someone is already on obesity medication before surgery, this report suggests a post-op plan may include revisiting medication strategy after SG, since many youths resumed the same medication class and fewer required multiagent therapy after surgery.

• Key timing detail in the study: median 1.0 month to restart medications in the early reinitiation group.
• What changed by 12 months: larger BMI percentage reduction and excess BMI loss percentage, plus larger improvements in eating behavior measures, in the early reinitiation group.
• What did not differ: reported postoperative complication categories listed in the paper summary.

Limitations and caveats to keep in view

This evidence comes from a research letter reporting outcomes in a relatively small sample (99 youths) who underwent sleeve gastrectomy, so the findings should be interpreted as observational associations within this specific group and setting.

The report summary does not provide details on specific drugs, doses, or the criteria used to decide who restarted medications, so readers should avoid assuming the same results would apply to every patient, medication, or surgical pathway.